Advertisement
Response from Dr. Sherer

As you have already experienced, there is an element of trial and error in all of medicine, and in HIV medicine.
I would encourage you to try the recommended Kivexa (combined abacavir and lamivudine in a once-daily formulation) and Reyataz, because it will be considerably more convenient if you happen to tolerate it as well as you do the Crixivan regimen that you are on.
My own preference, however, is not to use Reyataz alone, but only to use it with 'boosting' with ritonavir one tablet (100mg) once daily, in order to achieve higher drug levels (of Reyataz).
I would also want to ensure that you understand the nature of abacavir hypersensitivity reactions, which occur in 3-5% of people taking abacavir, which is the main side effect of that drug. And I would suggest that you be aware that 3-5% of people taking Reyataz become jaundiced or have some gi side effects, which are the main side effects of that drug.
I also would have agreed that a trial of Kaletra and Combivir was warranted, though you did not tolerate that regimen. You should be aware that there is a new forumulation of Kaletra - two tablets twice daily, or four tablets once daily - for which GI side effects are reduced, so you may respond differently to that drug in future.
Another alternative NRTI combination to consider is Truvada, which is co-formulated tenofovir plus emtricabine (FTC), and which is taken once daily.
Two last points: First, such treatment trials appear to be relatively risk free with the PI class (like Crixivan, Kaletra, and Reyataz), in that resistance to these drugs develops only very slowly. Hence there is little to be lost if you don't tolerate this second new regimen - you can always return to three times daily Crixivan.
Secondly, knowing that you have already experienced lipoatrophy, I would urge that you switch off of stavudine to alternative NRTIs ASAP, and stay off it, no matter what PI you end up taking, as stavudine is most strongly linked with lipoatrophy, and reversals of lipoatrophy begin once it is discontinued.
The switch from Crixivan is more for convenience, and still worthwhile.
Like most physicians, I still have patients who are on that Crixivan regimen and just prefer not to risk its good performance, in spite of all the simpler regimens. Nonetheless, most of my patients are able to tolerate a simpler regimen with equally positive outcomes.
I urge you to talk to your doctor about your questions and this response.
Want to read more questions and answers on this subject? Our experts have answered many similar questions!
|